<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373087</url>
  </required_header>
  <id_info>
    <org_study_id>P051034</org_study_id>
    <nct_id>NCT00373087</nct_id>
  </id_info>
  <brief_title>COMT Polymorphism and Entacapone Efficacy</brief_title>
  <acronym>COMT</acronym>
  <official_title>Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Entacapone is an antiparkinsonian drug which block L-dopa metabolism, inhibiting the
      C-O-methyltransferase (COMT) enzyme. There is an individual variability of the COMT activity
      determined by a genetic polymorphism. The aim of this study is to investigate whether the
      genetic variability influences entacapone efficacy in Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COMT protein is dependent of a single autosomal locus with two co-dominant alleles with a
      high activity (allele H) and a low activity (allele L) form of the enzyme. L and H allele
      frequency in the Caucasian population is around 50%. This is a monocentric randomized blinded
      cross-over study comparing acute challenge of L-dopa + placebo versus L-dopa + 200 mg
      entacapone, in Parkinson's disease patients with HH and LL genotypes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>L-dopa efficacy duration on UPDRS motor scale during an acute L-dopa test</measure>
    <time_frame>during the hospitalization in 24 hours</time_frame>
    <description>L-dopa efficacy duration on UPDRS motor scale during an acute L-dopa test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of L-dopa and its metabolites</measure>
    <time_frame>at the end of the study during the last hospitalization</time_frame>
    <description>Pharmacokinetics of L-dopa and its metabolites</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>L-dopa + entacapone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L-dopa + entacapone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L dopa / placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L dopa / placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entacapone</intervention_name>
    <description>entacapone</description>
    <arm_group_label>L-dopa + entacapone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>l dopa versus placebo</intervention_name>
    <description>l dopa versus placebo</description>
    <arm_group_label>L dopa / placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's disease

          -  wearing off

        Exclusion Criteria:

          -  atypical parkinsonism

          -  neuroleptic use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Christophe CORVOL, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique, Hôpital de la Pitié-Salpétrière,</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2006</study_first_submitted>
  <study_first_submitted_qc>September 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2006</study_first_posted>
  <last_update_submitted>April 28, 2010</last_update_submitted>
  <last_update_submitted_qc>April 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christophe Aucan</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Catechol O-methyltransferase</keyword>
  <keyword>Entacapone</keyword>
  <keyword>pharmacogenetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Entacapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

